Abstract
The combination of abciximab in full doses and reteplase in half doses did not significantly reduce the rate of mortality at 30 days in patients with acute ST-segment elevation myocardial infarction (MI) when compared with reteplase in full doses in the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO V) trial. However, subgroup analysis indicates that the combined regimen reduced the complications of acute MI, representing an important alternative strategy for pharmacologic reperfusion.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Abciximab
-
Aged
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Dose-Response Relationship, Drug
-
Drug Therapy, Combination
-
Fibrinolytic Agents / adverse effects
-
Fibrinolytic Agents / therapeutic use*
-
Hemorrhage / chemically induced
-
Humans
-
Immunoglobulin Fab Fragments / adverse effects
-
Immunoglobulin Fab Fragments / therapeutic use*
-
Myocardial Infarction / drug therapy*
-
Myocardial Infarction / mortality
-
Platelet Aggregation Inhibitors / adverse effects
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Recombinant Proteins / adverse effects
-
Recombinant Proteins / therapeutic use*
-
Recurrence
-
Tissue Plasminogen Activator / adverse effects
-
Tissue Plasminogen Activator / therapeutic use*
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Fibrinolytic Agents
-
Immunoglobulin Fab Fragments
-
Platelet Aggregation Inhibitors
-
Recombinant Proteins
-
reteplase
-
Tissue Plasminogen Activator
-
Abciximab